Higher HbA1c levels associate with lower hippocampal serotonin transporter availability in non-diabetic adults with obesity

Rico Grundmann1,2,3, Michael Rullmann1,2, Julia Luthardt1, Franziska Zientek2, Georg-Alexander Becker3, Marianne Patt1, Mohammed K. Hankir4,5, Matthias Blüher5,6, Osama Sabri1 & Swen Hesse1,2

The current study aimed to investigate whether the in vivo availability of central serotonin reuptake transporters (5-HTT) is associated with plasma levels of glycosylated hemoglobin (HbA1c) in non-diabetic humans with obesity. 5-HTT availability was measured by using positron emission tomography (PET) imaging with the 5-HTT selective radiotracer [11C]DASB in 23 non-diabetic individuals with obesity and 14 healthy, non-obesity controls. Parametric images of binding potential BPND were generated from the PET data and analyzed together with HbA1c levels by using volume of interest analysis for brain areas relevant to appetite control. Voxel-based morphometry (VBM) of individual magnetic resonance imaging (MRI) data was further performed to correlate grey matter density (GMD) maps with HbA1c. We found significant negative correlations between HbA1c levels and BPND in right and left hippocampus in obesity (r = − 0.717, p < 0.001, and r = − 0.557, p = 0.006, respectively). VBM analyses revealed that higher HbA1c levels were associated with GMD in the right para-hippocampal area. Our results indicate that chronically high blood glucose levels may evoke changes in hippocampal 5-HTT levels that are in part tied to local microstructure.

Abbreviations
[11C]DASB  3-Amino-4-(2-dimethylaminomethylphenylsulfanyl)-benzonitrile
5-HT  5-Hydroxytryptamine = Serotonin
5-HTT  Serotonin transporter
BDNF  Brain-derived neurotrophic factor
BMI  Body mass index
BPND  Non-displaceable binding potential
GMD  Grey matter density
HbA1c  Glycosylated hemoglobin
lH  Left hippocampus
MRI  Magnetic resonance imaging
PET  Positron emission tomography
rH  Right hippocampus
SN  Substantia nigra
SPECT  Single-photon emission computed tomography
T2DM  Type 2 diabetes mellitus
VBM  Voxel-based morphometry
VOI  Volume of interest
VTA  Ventral tegmental area

1Department of Nuclear Medicine, University of Leipzig, Liebigstraße 18, 04103 Leipzig, Germany. 2Integrated Research and Treatment Center (IFB) Adiposity Diseases, University of Leipzig, Leipzig, Germany. 3Sana Klinikum Borna, Klinik für Neurologie, Borna, Germany. 4Department of Experimental Surgery, University Hospital Wuerzburg, Wuerzburg, Germany. 5German Research Foundation Collaborative Research Center in Obesity Mechanisms 1052, University of Leipzig, Leipzig, Germany. 6Department of Internal Medicine, University of Leipzig, Leipzig, Germany. *email: swen.hesse@medizin.uni-leipzig.de
The pandemic spread of obesity and associated comorbidities such as type 2 diabetes mellitus (T2DM) has stimulated intense research efforts into its social, psychological as well as biological underpinnings. Although this has led to significant progress in our understanding of the central pathways that control food intake and energy metabolism, currently available obesity pharmacotherapies remain of relatively limited efficacy. Further insight into how feeding-regulatory neural circuits are targeted by central and peripheral factors, especially in human obesity, may therefore guide the development of novel treatments that cause greater weight loss.

At the molecular level, the central serotonin (5-hydroxytryptamine, 5-HT) system has well-established roles in regulating energy balance. Anti-serotonergic drugs have long been known to stimulate food intake\(^{12}\), whereas several selective 5-HT reuptake inhibitors acting on 5-HT reuptake transporters (5-HTT), which elevate synaptic 5-HT levels, suppress food intake\(^{3}\). In addition the selective 5-HT\(_{2C}\) receptor agonist lorcaserin is an approved obesity pharmacotherapy, which also has the potential to prevent progression from prediabetes to manifest T2DM\(^{4}\). Accordingly, lorcaserin directly targets hypothalamic and hindbrain neural circuits to suppress food intake and improve glycemic control in rodents\(^{34}\). It remains less clear, however, how peripheral factors influence the central serotonergic system in the context of obesity and T2DM pathogenesis, especially in humans.

Brain-derived neurotrophic factor (BDNF) is a neurotrophin that has an influence on energy metabolism, insulin sensitivity\(^*\) and glucose metabolism\(^*\), as well as on hippocampal microstructure by altering central 5-HT signaling\(^*\). Recently, we investigated the link between BDNF and the genetic regulation of central 5-HTT availability\(^{16}\). We showed a significant negative correlation between BDNF and hippocampal 5-HTT availability in homozygous L (L/L) carriers who have higher 5-HTT activity\(^{17}\). BDNF might thus act as an integrative key signal at the interface of glucose metabolism and 5-HTT dependent microstructure changes in hippocampus, which in turn could affect memory formation. It is therefore of interest whether there is a connection between BDNF and glycosylated hemoglobin levels (HbA1c), the variant of hemoglobin, chemically bound to glucose as a stable marker of blood glucose levels over a time period of approximately three months.

To the best of our knowledge, only one previous clinical study investigated central 5-HTT availability in lean and individuals with obesity and with or without insulin resistance, using single-photon emission computed tomography (SPECT) with the monoamine transporter-binding radiotracer \[^{[123]}\text{FP-CIT}\]. This study showed that radiotracer binding to 5-HTT in the diencephalon was lower in insulin-resistant individuals independently of body weight whereas hypothalamic 5-HTT binding was lower in individuals with obesity independently of insulin sensitivity\(^{12}\). However, the association between plasma HbA1c and central 5-HTT availability has not been explored so far in vivo with positron emission tomography (PET) in humans.

The main aim of the current study was therefore to investigate whether there is an association between central 5-HTT availability and plasma HbA1c levels in individuals with obesity but without manifest T2DM and in healthy controls without obesity. We hypothesized that 5-HTT availability is negatively associated with plasma HbA1c in brain areas that are relevant for energy homeostasis and food intake control, e.g. the hypothalamus and the prefrontal cortex, as well as for memory formation, i.e. the hippocampus. By applying PET and the radiolabeled 3-amino-4-(2-dimethylaminomethylphenylsulfanyl)-benzonitrile (\[^{[11]}\text{C}\text{DASB}\]), which binds to presynaptic 5-HTT with high selectivity, we calculated non-displaceable binding potential (BP\(_{\text{ND}}\)) as a marker for 5-HTT availability. We additionally performed voxel-based morphometry (VBM) analyses of magnetic resonance imaging (MRI) data to assess microstructural brain changes based on grey matter density (GMD) maps in association with plasma HbA1c levels\(^{17}\). Finally, we performed correlational analyses of HbA1c levels and serum BDNF levels in 5-HTT genotype stratified subgroups, i.e., L- and S-allele carriers\(^{10}\).

Materials and methods
**Study participants.** The study cohort represents a subset of previously published data\(^{14}\) consisting individuals with obesity and non-obesity controls for whom HbA1c assessments were available. We further excluded one individual with obesity due to prediabetic metabolism (HbA1c > 5.9%). Other exclusion criteria comprised current or past neurological or psychiatric illness, positive family history for psychiatric illnesses, former psychotherapy, resistant hypertension, type 1 and type 2 diabetes mellitus, the use of centrally-acting drugs, participation in weight loss programs during the last 6 months, past or present history of alcohol misuse and/or illicit drug abuse, as well as contraindications for MRI (e.g., implanted ferromagnetic devices, claustrophobia), pregnancy, or breast feeding\(^{14}\). Informed written consent was obtained prior to study inclusion as well as detailed medical history and clinical examinations.

PET imaging data and blood samples in 23 individuals with obesity with a body mass index (BMI) of 41.7 ± 4.9 kg/m\(^2\) (6 men; mean age: 36.1 ± 10.2 years; range 21–56 years) and 14 healthy, non-obesity controls (BMI: 22.5 ± 2.6 kg/m\(^2\); 5 men; mean age, 36.1 ± 7.2 years; range 21–49 years) were analyzed.

**Imaging.** All study participants received a PET scan as previously described\(^{14}\). Briefly, each study participant underwent a 90-min dynamic scan (23 frames: 4 × 15 s, 4 × 1 min, 5 × 2 min, 5 × 5 min, 5 × 10 min) using the ECAT EXACT HR+ tomograph (Siemens, Erlangen, Germany, intrinsic resolution at the center: 4.3 mm, axial resolution: 5–6 mm field of view 15.5 cm, 3–4 mm full width at half maximum) in a 3-dimensional acquisition mode. \[^{[11]}\text{C}\text{DASB}\] was synthesized according to the procedures reported by Wilson et al.\(^{15}\). With the start of each scan, 484.1 ± 9.9 MBq \[^{[11]}\text{C}\text{DASB}\] were injected intravenously as a continuous bolus over 90 s. A 10-min transmission scan (from three \[^{68}\text{Ga}\text{/68Ge}\] sources) prior to PET acquisition was used for attenuation correction and iterative reconstruction (10 iterations, 16 subsets) in transverse image series (63 slices, 128 × 128 matrix, voxel size 2.6 × 2.6 × 2.4 mm\(^3\)) with a Hann-filter (cut-off 4.9 mm) for post-processing was applied. MRI for the exclusion of structural brain abnormalities and for imaging data co-registration was performed on all study participants. T1-weighted MP-RAGE sequences were acquired on either a Siemens Verio or TimTrio 3 T scanner (Siemens, Erlangen, Germany).
Imaging data analysis. We co-registered a summed image of the first 13 frames of the PET data with individual 3D T1-weighted MP-RAGE MRI data, using PMOD software (Version 3.4) for re-alignment and stereotactical normalization according to the anterior posterior commissure line. Parametric images of BP\textsubscript{ND} were generated from the PET data by using a multi-linear reference tissue model with two parameters and the cerebellar cortex as a reference region. Regional analysis of BP\textsubscript{ND} values was performed by atlas-based manual delineation of volumes of interest (VOI), including the dorsolateral prefrontal cortex, the orbitofrontal cortex, the insula, the ventral striatum, the thalamus, the hypothalamus, the hippocampus, the midbrain, i.e. the substantia nigra (SN) and ventral tegmental area (VTA) and the raphe nuclei.

VBM analyses of MRI data to consider micro-structural changes were performed using VBM8 (http://www.neuro.uni-jena.de/vbm/) implemented in SPM8 (Statistical Parametric Mapping, Wellcome Department of Cognitive Neurology, UK) and Matlab 7.14.0 (The MathWorks Inc., USA). In agreement with general practice, we used the term GMD to describe the normalized grey matter probability values.

Blood plasma analysis. We collected venous blood from all study participants immediately before the start of the PET scan. Plasma was immediately collected by centrifugation and refrigerated for subsequent HbA1c (non-diabetic: \(\leq 5.9\%\)) and BDNF measurements. We excluded one individual with obesity due to pre-start of the PET scan. Plasma was immediately collected by centrifugation and refrigerated for subsequent diabetic metabolism (HbA1c > 5.9%) resulting in samples from 23 participants with obesity and 14 non-obesity controls for final analysis.

Statistical analysis. The data were analyzed using SPSS 22 software (SPSS Inc., Chicago, IL). All data are presented as mean and standard deviation. After testing our data for normal distribution using Shapiro-Wilk test \((p > 0.05)\) Pearson product moment correlation was used to test for an association between blood parameters and 5-HTT BP\textsubscript{ND} as well as volume values from our VOI measurements, respectively. Contributing to our previous study\textsuperscript{16}, we subdivided our whole cohort (obese and non-obese) genotype depended in a homozygous L (L/L) and a homozygous plus heterozygous S genotyped (S +) group for group comparisons of serum BDNF and HbA1c levels. Unless otherwise stated, statistical significance was defined as \(a < 0.05\) and two-tailed. Graphical presentations were created using GraphPad Prism 7.04 (GraphPad Software Inc., La Jolla, CA, www.graphpad.com) for Windows.

For voxel-based analysis, we used an uncorrected threshold of \(p < 0.001\) in SPM8 while correlating GMD maps (MRI) with HbA1c levels, as well as 5-HTT BP\textsubscript{ND} as well as volume values from our VOI measurements, respectively. Contributing to our previous findings for GMD-HbA1c associations\textsuperscript{16} as provided in Automated Anatomical Labeling atlas\textsuperscript{17}.

Ethics statement. The study was performed after authorization by the ethics committee of the Medical Faculty of the University of Leipzig (registered under no. 206-10-08032010). The study was registered at the European clinical trial database (EudraCT 2012-000568-32) and the German Clinical Trials Register (DRKS), and was accomplished in agreement with all provisions declared by the ICH Guideline for Good Clinical Practice (GCP), the declaration of Helsinki, and the German Federal Office for Radiation Protection (registered under no. Z5-22461-2-2011-002).

Results

Between-group comparison of BP\textsubscript{ND} and HbA1c levels. The results of HbA1c and BP\textsubscript{ND} analyses are summarized in Table 1. There was no significant group-difference of HbA1c and BP\textsubscript{ND} between individuals with obesity and without obesity.

Correlative analyses of BP\textsubscript{ND} and HbA1c. We found highly significant negative correlations between HbA1c levels and BP\textsubscript{ND} in the right (rH, Fig. 1) and left hippocampus (lH, Fig. 2) in participants with obesity (rH: \(r = 0.717, p < 0.001; \) lH: \(r = 0.557, p = 0.006\)), but not in the group of healthy controls without obesity (rH: \(r = 0.138, p = 0.64; \) lH: \(r = 0.091, p = 0.76\)). The differences of the regression coefficients were significant (rH: \(p = 0.001\); lH: \(p = 0.03\)). Partial correlations with “age” and “sex” as nuisance variable confirm the significant correlation results (“age”: rH: \(r = 0.704, p < 0.001; \) lH: \(r = 0.516, p = 0.014; \) “sex”: rH: \(r = 0.754, p < 0.001; \) lH: \(r = 0.561, p = 0.007\)). We did not find significant correlations between 5-HTT BP\textsubscript{ND} and HbA1c levels in any of the other investigated VOIs.

Voxel-based morphometry. Higher HbA1c levels were associated with GMD in the right para-hippocampal area (Fig. 3; MNI: \(x = 22.5, y = 11, z = -22.5\) mm; 18 voxels; \(T > 3.91, p < 0.001\) uncorrected). VBM correlative analysis separated into obesity-versus-non-obesity group indicated no correlation in non-obesity, while obesity cohort showed a similar but smaller cluster of a correlation between GMD and HbA1c levels in the right hippocampus (\(x = 20, y = 11, z = -23\) mm; 5 voxels). There was no significant correlation between 5-HTT BP\textsubscript{ND} and GMD in hippocampus or the para-hippocampal area.

Correlative analyses of HbA1c and BDNF. Pearson correlation did not reveal a general relationship between serum BDNF and HbA1c levels in the whole cohort. Genotype stratified group analyses showed a significant negative correlation in the S + group (\(r = -0.53; p = 0.034\); Fig. 4).
Table 1. Demographics and 5-HTT BPND from volume-of-interest (VOI) analysis obtained with $^{11}$C]DASB and PET. SN substantia nigra, VTA ventral tegmental area. Bold value indicates statistically significant group differences (p < 0.05). a BMI > 35 kg/m2. b BMI < 27 kg/m2. c Student’s t-test except for sex and smoking habits (Fisher’s Exact test).

|                        | Obesitya | Non-Obesityb | p valuec |
|------------------------|----------|--------------|----------|
| N                      | 23       | 14           |          |
| Demographics           |          |              |          |
| Sex (women/men)        | 17/6     | 9/5          | 0.71     |
| Smoking habits (no/occasionally/yes) | 13/1/1 | 17/2/6 | 0.40 |
| Age (years)            | 36.1 ± 10.2 | 36.1 ± 7.2 | 0.996   |
| BMI (kg/m2)            | 41.1 ± 4.9 | 22.5 ± 2.6 | < 0.0001 |
| HbA1c (%)              | 5.57 ± 0.30 | 5.54 ± 0.30 | 0.5     |
| VOIs                   |          |              |          |
| Dorsolateral prefrontal cortex right | 0.24 ± 0.14 | 0.21 ± 0.08 | 0.52   |
| Dorsolateral prefrontal cortex left | 0.25 ± 0.14 | 0.22 ± 0.08 | 0.57   |
| Orbitofrontal cortex right | 0.45 ± 0.18 | 0.41 ± 0.10 | 0.43   |
| Orbitofrontal cortex left | 0.46 ± 0.17 | 0.40 ± 0.13 | 0.25   |
| Insula right           | 0.66 ± 0.2 | 0.63 ± 0.16 | 0.7    |
| Insula left            | 0.68 ± 0.23 | 0.64 ± 0.13 | 0.56   |
| Ventral striatum       | 1.54 ± 0.39 | 1.56 ± 0.37 | 0.84   |
| Ventral striatum       | 1.62 ± 0.47 | 1.65 ± 0.37 | 0.82   |
| Amygdala right         | 1.32 ± 0.37 | 1.2 ± 0.34 | 0.34    |
| Amygdala left          | 1.35 ± 0.4 | 1.27 ± 0.33 | 0.56   |
| Raphé                  | 3.44 ± 0.87 | 3.09 ± 0.67 | 0.2     |
| Thalamus right         | 1.62 ± 0.51 | 1.48 ± 0.33 | 0.38   |
| Thalamus left          | 1.53 ± 0.52 | 1.37 ± 0.39 | 0.32   |
| Hypothalamus right     | 2.11 ± 0.55 | 1.78 ± 0.53 | 0.08   |
| Hypothalamus left      | 2.09 ± 0.62 | 1.93 ± 0.52 | 0.45   |
| Hippocampus right      | 0.58 ± 0.29 | 0.2 ± 0.13 | 0.47   |
| Hippocampus left       | 0.64 ± 0.27 | 0.54 ± 0.2 | 0.22   |
| SN/VTA right           | 1.58 ± 0.52 | 1.55 ± 0.52 | 0.89 |
| SN/VTA left            | 1.58 ± 0.53 | 1.55 ± 0.5 | 0.86   |

Figure 1. Scatterplot showing Pearson correlation between HbA1c levels and 5-HTT BPND obtained with $^{11}$C]DASB and PET in right hippocampus (rH) for obese ($r = -0.79$, $p = 0.0002$) and non-obese ($r = 0.06$, $p = 0.64$). The difference of regression coefficients was significant ($p = 0.002$).
Discussion

To our knowledge, this is the first study investigating the association between the central in-vivo 5-HTT availability using $^{[1]}$C DASB and PET with plasma HbA1c in human obesity. We observed a significant age- and sex-independent negative effect of higher HbA1c levels on 5-HTT availability in the hippocampus of non-diabetic individuals with obesity but not in controls without obesity. VBM revealed HbA1c-dependent microstructural changes in the right para-hippocampal area. These findings contribute to the aforementioned assumption of chronically high glucose levels evoking hippocampal (micro-) structural alterations. We found a small cluster a correlation between GMD and HbA1c in the right hippocampus of our individuals with obesity but no correlation in the non-obesity group. The lack of further differences between the obesity and the nonobesity group in the voxel-based correlation is primary explained as a consequence of a small sample size. Nonetheless, our data point to a hippocampal vulnerability for increased HbA1c reflected by GMD changes and altered 5-HTT signaling in obesity that occur in the absence of, or possibly prior to, manifest T2DM.

Contrary to our initial hypothesis, we did not find correlations between HbA1c and 5-HTT availability in other brain areas that are implicated in energy homeostasis and the control of food intake, e.g. the hypothalamus and the prefrontal cortex. Altogether, differences in HbA1c levels only have an effect on hippocampal 5-HTT availability in individuals with obesity.

In can therefore be speculated whether weight gain and obesity are linked with a hippocampal-dependent process of energy dysregulation and decreased hippocampal performance. Specifically, obesity and consumption of high-fat diet can lead to impaired hippocampal cognitive functions, i.e. impaired learning about the relationship between food cues and rewarding signals, which in turn can result in attenuated cognitive control of food intake, displaying a vicious cycle of weight gain and cognitive decline. In line with this, medial temporal lobe damage in humans, which involves hippocampal damage, leads to difficulties in utilizing certain information presented by their internal cues, e.g. interoceptive stimuli corresponding to hunger and satiety. In addition, studies reveal that inhibition of food intake to an extent depends on activation of neural pathways between the hippocampus and the lateral hypothalamus. We propose that HbA1c-dependent alterations in hippocampal 5-HT signaling in obesity is an essential part of these processes. If this is a mechanism linked to alterations in memory consolidation needs to be further tested.

Corroborating our previous findings, we showed that BDNF acts in a 5-HTT genotype-dependent manner. Here, 5-HTT genotyping analysis revealed a significant negative correlation between HbA1c and BDNF in S+ subgroup. Accordingly, exercise-induced decrease in some diabetic risk factors, such as fasting glucose levels, are associated with elevated BDNF levels in adults with obesity. Moreover, carriers of the functional BDNFVal66Met allele who have raised HbA1c levels showed impaired episodic memory and thus, BDNFVal66Met and elevated HbA1c might act synergistically in cognitive aging. Correspondingly, an involvement of BDNF has been identified in the pathogenesis not only of T2DM, but also of dementia and depression. Thus, genotype-defined modifications of central hippocampal 5-HT signaling might play a role in these frameworks of allostatic and allostatic overload. However, the exact function of serotonergic actions and hippocampal formation in human obesity has yet to be clarified and tested prospectively in enlarged study cohorts with 1:1 case–control design, which could be not applied in our current study (as a major limitation). We also did not obtain fasting blood glucose, which may have an influence on study results, either. Further studies are necessary to determine the link between glucose metabolism, peripheral hormones (such as GLP-1, leptin and ghrelin), BDNF and hippocampal 5-HTT signaling and its biological relevance with regard to preventive and therapeutic consequences in individuals with obesity.

Figure 2. Scatterplot showing Pearson correlation between HbA1c levels and 5-HTT BPND obtained with $^{[1]}$C DASB and PET in the left hippocampus (lH) individuals with obesity ($r = -0.57$, $p = 0.006$) and non-obesity ($r = 0.056$, $p = 0.76$). The difference of regression coefficients was statistically significant ($p = 0.03$).
Figure 3. Voxel based morphometry analyses. Correlation between GMD and HbA1c, which showed clusters in parahippocampal region in the right hemisphere (18 voxels, MNI: x = 22.5, y = 11, z = −22.5 mm, T > 3.91, p < 0.001).
Figure 4. Scatterplot showing Pearson correlation between serum BDNF and HbA1c levels in S-carriers ($r = -0.531, p = 0.034$).

Data availability

All study–associated data and material is stored at the Department of Nuclear Medicine, University of Leipzig, and access is available by request.

Received: 12 June 2020; Accepted: 27 October 2020
Published online: 07 December 2020

References

1. Bergen, S. S. Appetite stimulating properties of cyproheptadine. Am. J. Dis. Child. 1960(108), 270–273 (1964).
2. Guy-Grand, B. Clinical studies with dexfenfluramine: from past to future. Obes. Res. 3(Suppl 4), 491S–496S (1995).
3. Hafed, J., Harrold, J., Lawton, C. & Blundell, J. Serotonin (5-HT) drugs: effects on appetite expression and use for the treatment of obesity. Curr. Drug Targets. 6(2), 201–213 (2005).
4. Nesto, R., Fain, R., Li, Y. & Shanahan, W. Evaluation of lorcaserin on progression of prediabetes to type 2 diabetes and reversion to euglycemia. Postgrad. Med. 128(4), 364–370 (2016).
5. Burke, L. K. et al. Lorcaserin improves glycemic control via a melanocortin neurocircuit. Mol. Metab. 6(10), 1092–1102 (2017).
6. D’Agostino, G. et al. Nucleus of the solitary tract serotonin 5-HT2C receptors modulate food intake. Cell Metabol. 28(4), 619-630. e5 (2018).
7. Kernie, S. G., Liebl, D. J. & Parada, L. F. BDNF regulates eating behavior and locomotor activity in mice. EMBO J. 19(6), 1290–1300 (2000).
8. Tonra, J. R. Evaluation of lorcaserin on progression of prediabetes to type 2 diabetes and reversion to euglycemia. Postgrad. Med. 128(4), 364–370 (2016).
9. Halford, J., Harrold, J., Lawton, C. & Blundell, J. Serotonin (5-HT) drugs: effects on appetite expression and use for the treatment of obesity. Curr. Drug Targets. 6(2), 201–213 (2005).
10. Hinderberger, P. et al. The effect of serum BDNF levels on central serotonin transporter availability in obese versus non-obese adults: A (11)C-DASB positron emission tomography study. Neuropharmacology 110(PT A), 530–536 (2016).
11. Lesch, K. P. et al. Regional brain expression of serotonin transporter mRNA and its regulation by reuptake inhibiting antidepressants. Brain Res. Mol. Brain Res. 17(1–2), 31–35 (1993).
12. Versteeg, R. I. et al. Serotonin transporter binding in the diencephalon is reduced in insulin-resistant obese humans. Neuroendocrinology 105(2), 141–149 (2017).
13. Mueller, K. et al. Obesity associated cerebral gray and white matter alterations are interrelated in the female brain. PLoS ONE 9(12), e114206 (2014).
14. Wilson, A. A. et al. Novel radiotracers for imaging the serotonin transporter by positron emission tomography. Neuroreport 3(16), 3103–3110 (2000).
15. Wilson, A. A. et al. Novel radiotracers for imaging the serotonin transporter by positron emission tomography. J. Med. Chem. 48(2), 364–370 (2005).
16. Wilson, A. A. et al. Novel radiotracers for imaging the serotonin transporter by positron emission tomography. J. Med. Chem. 48(2), 364–370 (2005).
17. Wilson, A. A. et al. Novel radiotracers for imaging the serotonin transporter by positron emission tomography. J. Med. Chem. 48(2), 364–370 (2005).
18. Wilson, A. A. et al. Novel radiotracers for imaging the serotonin transporter by positron emission tomography. J. Med. Chem. 48(2), 364–370 (2005).
19. Wilson, A. A. et al. Novel radiotracers for imaging the serotonin transporter by positron emission tomography. J. Med. Chem. 48(2), 364–370 (2005).
20. Wilson, A. A. et al. Novel radiotracers for imaging the serotonin transporter by positron emission tomography. J. Med. Chem. 48(2), 364–370 (2005).
21. Wilson, A. A. et al. Novel radiotracers for imaging the serotonin transporter by positron emission tomography. J. Med. Chem. 48(2), 364–370 (2005).
22. Wilson, A. A. et al. Novel radiotracers for imaging the serotonin transporter by positron emission tomography. J. Med. Chem. 48(2), 364–370 (2005).
23. Wilson, A. A. et al. Novel radiotracers for imaging the serotonin transporter by positron emission tomography. J. Med. Chem. 48(2), 364–370 (2005).
24. Wilson, A. A. et al. Novel radiotracers for imaging the serotonin transporter by positron emission tomography. J. Med. Chem. 48(2), 364–370 (2005).
25. Wilson, A. A. et al. Novel radiotracers for imaging the serotonin transporter by positron emission tomography. J. Med. Chem. 48(2), 364–370 (2005).
Acknowledgements
This study was supported by the German Federal Ministry of Education and Research (FKZ: 01EO1001).

Author contributions
S.H. and O.S. conceived the study. R.G., M.R., J.L., E.Z., G.B., M.P., M.B., O.S. and S.H. contributed to the acquisition, processing, and interpretation of the data. R.G. performed the data analysis and drafted the manuscript. M.R. contributed to data analysis, figure creation and helped in writing the paper. S.H., O.S., M.R., and M.K.H. critically revised the paper for important intellectual content. M.K.H. proofread the manuscript as native English speaker. S.H. approved the final manuscript. All authors have read and agreed to the published version of this study.

Funding
Open Access funding enabled and organized by Projekt DEAL. We acknowledge support from Leipzig University for Open Access Publishing.

Competing interests
The authors declare no competing interests.

Additional information
Correspondence and requests for materials should be addressed to S.H.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2020